PITX2 Methylation: a Novel and Effective Biomarker for Monitoring Biochemical Recurrence Risk of Prostate Cancer

Overview

Journal Medicine (Baltimore)

Specialty General Medicine

Date 2019 Jan 5

PMID 30608394

Citations 3

Authors

Qi Jiang

Mixue Xie

Mengye He

Feifei Yan

Ming Chen

Suzhen Xu

Xiaochen Zhang

Peng Shen

Affiliations

Soon will be listed here.

Abstract

Aims: Prostate cancer is one of the most common malignancies in men. Biochemical recurrence (BCR) and progression following curative treatment pose a significant public health challenge. Thus, it is essential to explore effective biomarkers for disease progression monitoring and risk stratification. The promoter region of the paired-like homeodomain transcription factor 2 (PITX2) gene has been found to be frequently methylated in prostate cancer. However, the prognostic role of PITX2 methylation in prostate cancer and which patients most likely to be recommended for PITX2 methylation tests to assess BCR risk remain controversial. Therefore, a systematic review was performed to explore the relationship of PITX2 methylation with the BCR risk of prostate cancer.

Methods: The PubMed, EMBASE, and Cochrane Library databases were systematically searched for eligible studies. Seven studies with a total of 2185 patients were included. Pooled hazard ratios (HRs) and corresponding 95% confidence intervals (CIs) were calculated.

Results: The overall HR was 2.71 (95% CI, 2.21-3.31), suggesting that PITX2 methylation has an adverse impact on BCR of prostate cancer. The pooled estimate of 5-year BCR-free survival for patients with a high methylation status was significantly lower than that for patients with a low methylation status (71% vs 90%; odds ratio [OR] = 3.50; 95% CI, 2.67-4.60, P = .000). A subgroup analysis was conducted according to detection method; the combined HRs were 2.68 (95% CI, 2.02-3.55) for quantitative methylation-specific PCR (qMSP) and 3.29 (95% CI, 2.31-4.68) for microarray EpiChip. In subgroups defined by region, Gleason score, pathological stage, surgical margin status and ethnicity, high methylation status was also associated with BCR of prostate cancer.

Conclusions: As an effective biomarker, PITX2 methylation is feasible for individualized BCR risk assessment of prostate cancer following radical prostatectomy.

Citing Articles

Overexpression of MUC1 Induces Non-Canonical TGF-β Signaling in Pancreatic Ductal Adenocarcinoma.

Bose M, Grover P, Sanders A, Zhou R, Ahmad M, Shwartz S Front Cell Dev Biol. 2022; 10:821875.

PMID: 35237602 PMC: 8883581. DOI: 10.3389/fcell.2022.821875.

Signature Panel of 11 Methylated mRNAs and 3 Methylated lncRNAs for Prediction of Recurrence-Free Survival in Prostate Cancer Patients.

Cai J, Yang F, Chen X, Huang H, Miao B Pharmgenomics Pers Med. 2021; 14:797-811.

PMID: 34285549 PMC: 8285280. DOI: 10.2147/PGPM.S312024.

Pitx genes in development and disease.

Tran T, Kioussi C Cell Mol Life Sci. 2021; 78(11):4921-4938.

PMID: 33844046 PMC: 11073205. DOI: 10.1007/s00018-021-03833-7.

References

Anglim P, Galler J, Koss M, Hagen J, Turla S, Campan M . Identification of a panel of sensitive and specific DNA methylation markers for squamous cell lung cancer. Mol Cancer. 2008; 7:62. PMC: 2483990. DOI: 10.1186/1476-4598-7-62. View

Ellinger J, Bastian P, Jurgan T, Biermann K, Kahl P, Heukamp L . CpG island hypermethylation at multiple gene sites in diagnosis and prognosis of prostate cancer. Urology. 2008; 71(1):161-7. DOI: 10.1016/j.urology.2007.09.056. View

Litovkin K, Joniau S, Lerut E, Laenen A, Gevaert O, Spahn M . Methylation of PITX2, HOXD3, RASSF1 and TDRD1 predicts biochemical recurrence in high-risk prostate cancer. J Cancer Res Clin Oncol. 2014; 140(11):1849-61. DOI: 10.1007/s00432-014-1738-8. View

Cottrell S, Jung K, Kristiansen G, Eltze E, Semjonow A, Ittmann M . Discovery and validation of 3 novel DNA methylation markers of prostate cancer prognosis. J Urol. 2007; 177(5):1753-8. DOI: 10.1016/j.juro.2007.01.010. View

Toyota M, Kopecky K, Toyota M, Jair K, Willman C, Issa J . Methylation profiling in acute myeloid leukemia. Blood. 2001; 97(9):2823-9. DOI: 10.1182/blood.v97.9.2823. View

Henrique R, Ribeiro F, Fonseca D, Hoque M, Carvalho A, Costa V . High promoter methylation levels of APC predict poor prognosis in sextant biopsies from prostate cancer patients. Clin Cancer Res. 2007; 13(20):6122-9. DOI: 10.1158/1078-0432.CCR-07-1042. View

Yoon H, Kim S, Kim Y, Kang H, Lee S, Ryu K . Combined hypermethylation of APC and GSTP1 as a molecular marker for prostate cancer: quantitative pyrosequencing analysis. J Biomol Screen. 2012; 17(7):987-92. DOI: 10.1177/1087057112444445. View

Uhl B, Gevensleben H, Tolkach Y, Sailer V, Majores M, Jung M . PITX2 DNA Methylation as Biomarker for Individualized Risk Assessment of Prostate Cancer in Core Biopsies. J Mol Diagn. 2016; 19(1):107-114. DOI: 10.1016/j.jmoldx.2016.08.008. View

Stephenson A, Kattan M, Eastham J, Dotan Z, Bianco Jr F, Lilja H . Defining biochemical recurrence of prostate cancer after radical prostatectomy: a proposal for a standardized definition. J Clin Oncol. 2006; 24(24):3973-8. DOI: 10.1200/JCO.2005.04.0756. View

10.

Taplin M . Biochemical (Prostate-Specific Antigen) Relapse: An Oncologist's Perspective. Rev Urol. 2006; 5 Suppl 2:S3-S13. PMC: 1502329. View

11.

Vinarskaja A, Schulz W, Ingenwerth M, Hader C, Arsov C . Association of PITX2 mRNA down-regulation in prostate cancer with promoter hypermethylation and poor prognosis. Urol Oncol. 2011; 31(5):622-7. DOI: 10.1016/j.urolonc.2011.04.010. View

12.

Banez L, Sun L, van Leenders G, Wheeler T, Bangma C, Freedland S . Multicenter clinical validation of PITX2 methylation as a prostate specific antigen recurrence predictor in patients with post-radical prostatectomy prostate cancer. J Urol. 2010; 184(1):149-56. DOI: 10.1016/j.juro.2010.03.012. View

13.

Cookson M, Aus G, Burnett A, Canby-Hagino E, DAmico A, Dmochowski R . Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in.... J Urol. 2007; 177(2):540-5. DOI: 10.1016/j.juro.2006.10.097. View

14.

Deeks J, Macaskill P, Irwig L . The performance of tests of publication bias and other sample size effects in systematic reviews of diagnostic test accuracy was assessed. J Clin Epidemiol. 2005; 58(9):882-93. DOI: 10.1016/j.jclinepi.2005.01.016. View

15.

Mir M, Li J, Klink J, Kattan M, Klein E, Stephenson A . Optimal definition of biochemical recurrence after radical prostatectomy depends on pathologic risk factors: identifying candidates for early salvage therapy. Eur Urol. 2013; 66(2):204-10. DOI: 10.1016/j.eururo.2013.08.022. View

16.

Alumkal J, Zhang Z, Humphreys E, Bennett C, Mangold L, Carducci M . Effect of DNA methylation on identification of aggressive prostate cancer. Urology. 2008; 72(6):1234-9. PMC: 2874954. DOI: 10.1016/j.urology.2007.12.060. View

17.

Bastian P, Ellinger J, Wellmann A, Wernert N, Heukamp L, Muller S . Diagnostic and prognostic information in prostate cancer with the help of a small set of hypermethylated gene loci. Clin Cancer Res. 2005; 11(11):4097-106. DOI: 10.1158/1078-0432.CCR-04-1832. View

18.

Fitzmaurice C, Akinyemiju T, Al Lami F, Alam T, Alizadeh-Navaei R, Allen C . Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2016: A Systematic Analysis for the Global Burden of Disease Study. JAMA Oncol. 2018; 4(11):1553-1568. PMC: 6248091. DOI: 10.1001/jamaoncol.2018.2706. View

19.

Schatz P, Dietrich D, Koenig T, Burger M, Lukas A, Fuhrmann I . Development of a diagnostic microarray assay to assess the risk of recurrence of prostate cancer based on PITX2 DNA methylation. J Mol Diagn. 2010; 12(3):345-53. PMC: 2860471. DOI: 10.2353/jmoldx.2010.090088. View

20.

Kioussi C, Briata P, Baek S, Rose D, Hamblet N, Herman T . Identification of a Wnt/Dvl/beta-Catenin --> Pitx2 pathway mediating cell-type-specific proliferation during development. Cell. 2002; 111(5):673-85. DOI: 10.1016/s0092-8674(02)01084-x. View